Litcius/Paper detail

Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting

Jonas Zimmermann, Janis Sonnemann, Wolfram J. Jabs, Ulf Schönermarck, Volker Vielhauer, Markus Bieringer, Udo Schneider, Ralph Kettritz, Adrian Schreiber

2024Kidney International Reports24 citationsDOIOpen Access PDF

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV) represents a group of systemic autoimmune small vessel vasculitis, leading to significant morbidity and mortality due to extensive organ damage (including kidney failure)1 and treatment toxicity to medications such as glucocorticoids.2 Thus, research focuses on developing treatment that minimize glucocorticoid use.

Topics & Concepts

MedicineAutoantibodyVasculitisImmunologyAnti-neutrophil cytoplasmic antibodyGlucocorticoidMicroscopic polyangiitisKidneySystemic vasculitisAntibodyPathologyInternal medicineDiseaseVasculitis and related conditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaAtherosclerosis and Cardiovascular Diseases
Avacopan in Anti-Neutrophil Cytoplasmic Autoantibodies–Associated Vasculitis in a Real-World Setting | Litcius